{"id":3429,"date":"2021-09-08T09:14:48","date_gmt":"2021-09-08T00:14:48","guid":{"rendered":"https:\/\/clarivate.com\/ja\/?p=3429"},"modified":"2021-09-08T09:14:48","modified_gmt":"2021-09-08T00:14:48","slug":"type-2-diabetes-in-mainland-china-shifting-treatment-patterns","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/ja\/blog\/type-2-diabetes-in-mainland-china-shifting-treatment-patterns\/","title":{"rendered":"\u4e2d\u56fd\u672c\u571f\u306b\u304a\u3051\u308b2\u578b\u7cd6\u5c3f\u75c5: \u6cbb\u7642\u30d1\u30bf\u30fc\u30f3\u306e\u5909\u5316"},"content":{"rendered":"<p><a href=\"https:\/\/clarivate.com\/blog\/type-2-diabetes-in-mainland-china-shifting-treatment-patterns\/\">\u82f1\u8a9e\u539f\u6587\u30b5\u30a4\u30c8<\/a><\/p>\n<p><span style=\"font-size: small\">\u672c\u8a18\u4e8b\u306f\u82f1\u6587\u30d6\u30ed\u30b0\u3092\u65e5\u672c\u8a9e\u306b\u7ffb\u8a33\u518d\u7de8\u96c6\uff08\u4e00\u90e8\u8ffd\u8a18\u3092\u542b\u3080\uff09\u3057\u305f\u3082\u306e\u3067\u3059\u3002\u672c\u8a18\u4e8b\u306e\u6b63\u5f0f\u8a00\u8a9e\u306f\u82f1\u8a9e\u3067\u3042\u308a\u3001\u305d\u306e\u5185\u5bb9\u30fb\u89e3\u91c8\u306b\u3064\u3044\u3066\u306f\u82f1\u8a9e\u304c\u512a\u5148\u3057\u307e\u3059\u3002<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><strong>KARAN VERMA<\/strong><br \/>\nPrincipal Analyst, Clarivate<\/p>\n<p>&nbsp;<\/p>\n<p><em>\u4e2d\u56fd\u672c\u571f\u3067\u306f\u8fd1\u5e74\u3001\u30c0\u30a4\u30ca\u30df\u30c3\u30af\u306a\u7d4c\u6e08\u72b6\u6cc1\u3084\u4eba\u53e3\u52d5\u614b\u306b\u5bfe\u5fdc\u3059\u308b\u305f\u3081\u306b\u3001\u898f\u5236\u3084\u511f\u9084\u306b\u95a2\u3059\u308b\u4e00\u9023\u306e\u6539\u9769\u304c\u884c\u308f\u308c\u3066\u304d\u307e\u3057\u305f\u3002\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u5e02\u5834\u8a55\u4fa1\u30a8\u30ad\u30b9\u30d1\u30fc\u30c8\u3067\u3042\u308bKaran Verma\u304c\u3001\u4e2d\u56fd\u672c\u571f\u306e2\u578b\u7cd6\u5c3f\u75c5\u5e02\u5834\u306b\u304a\u3051\u308b\u3053\u308c\u3089\u306e\u6539\u9769\u306e\u5f79\u5272\u3068\u3001\u9769\u65b0\u7684\u306a\u533b\u85ac\u54c1\u3078\u306e\u30a2\u30af\u30bb\u30b9\u3092\u3069\u306e\u3088\u3046\u306b\u5e83\u3052\u3089\u308c\u308b\u304b\u306b\u3064\u3044\u3066\u89e3\u8aac\u3057\u307e\u3059\u3002<\/em><\/p>\n<p>&nbsp;<\/p>\n<h4><strong>\u4e2d\u56fd\u672c\u571f\u306e2\u578b\u7cd6\u5c3f\u75c5\u306f\u9ad8\u3044\u6210\u9577\u7387\u3092\u7dad\u6301\u3057\u3066\u3044\u308b<\/strong><\/h4>\n<p>\u4e2d\u56fd\u672c\u571f\u3067\u306f\u300110\u4eba\u306b1\u4eba\u3001\u7d041\u51044,000\u4e07\u4eba\u304c2\u578b\u7cd6\u5c3f\u75c5\u3092\u60a3\u3063\u3066\u3044\u308b\u3068\u63a8\u5b9a\u3055\u308c\u3066\u3044\u307e\u3059<sup>1,4<\/sup>\u3002\u3053\u308c\u306f\u3001\u904e\u53bb\u6570\u5341\u5e74\u306b\u308f\u305f\u308b\u4e2d\u56fd\u306e\u6025\u901f\u306a\u90fd\u5e02\u5316\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002\u4e2d\u56fd\u3067\u306f\u3001\u30d6\u30c9\u30a6\u7cd6\u306e\u8178\u7ba1\u5438\u53ce\u3092\u4f4e\u4e0b\u3055\u305b\u3001\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3092\u9ad8\u3081\u308b\u3053\u3068\u3067\u8840\u7cd6\u5024\u3092\u9069\u5207\u306b\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3059\u308b\u3001\u3044\u304f\u3064\u304b\u306e\u6297\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85ac\u304c\u8ca9\u58f2\u3055\u308c\u3066\u3044\u307e\u3059<sup>4<\/sup>\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>\u52b9\u679c\u7684\u306aT2D\u6cbb\u7642\u85ac\u306e\u5c0e\u5165\u3092\u59a8\u3052\u3066\u3044\u308b\u65ad\u7247\u7684\u306a\u898f\u5236\u74b0\u5883<\/strong><\/h4>\n<p>\u5f93\u6765\u3001\u4e2d\u56fd\u672c\u571f\u306eT2D\u60a3\u8005\u306e\u591a\u304f\u306f\u3001\u5165\u624b\u306e\u3057\u3084\u3059\u3055\u3001\u8cbb\u7528\u5bfe\u52b9\u679c\u306e\u9ad8\u3044\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u533b\u85ac\u54c1\u306e\u5165\u624b\u53ef\u80fd\u6027\u3001HbA1c\u5024\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u52b9\u679c\u306e\u8a8d\u8b58\u306a\u3069\u304b\u3089\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3067\u306f\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u3001\u30bb\u30ab\u30f3\u30c9\u30e9\u30a4\u30f3\u6cbb\u7642\u3067\u306f\u30a2\u30ab\u30eb\u30dc\u30fc\u30b9\u3001\u30b9\u30eb\u30db\u30cb\u30eb\u5c3f\u7d20\u3001\u30c1\u30a2\u30be\u30ea\u30b8\u30f3\u7cfb\u85ac\u5264\u306a\u3069\u306e\u6a19\u6e96\u7684\u306a\u6297\u7cd6\u5c3f\u75c5\u6cbb\u7642\u3092\u53d7\u3051\u3066\u304d\u307e\u3057\u305f\u3002\u3053\u308c\u3089\u306e\u6cbb\u7642\u85ac\u306b\u306f\u3001\u4f53\u91cd\u5897\u52a0\u3001\u5fc3\u8840\u7ba1\u7cfb\u306e\u5b89\u5168\u6027\u306b\u95a2\u3059\u308b\u61f8\u5ff5\u3001\u4f4e\u8840\u7cd6\u306e\u767a\u751f\u7387\u306e\u9ad8\u3055\u306a\u3069\u306e\u526f\u4f5c\u7528\u304c\u3042\u308b\u3082\u306e\u306e\u3001\u8840\u7cd6\u5024\u3092\u4e0b\u3052\u308b\u52b9\u679c\u304c\u3042\u308b\u305f\u3081\u3001\u4f7f\u7528\u7387\u306f\u9ad8\u3044\u307e\u307e\u3067\u3057\u305f\u3002<\/p>\n<p>\u3057\u304b\u3057\u3001SGLT-2\u963b\u5bb3\u5264\u3084GLP-1\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u306a\u3069\u3001\u5f93\u6765\u306e\u6cbb\u7642\u85ac\u3088\u308a\u3082\u4f53\u91cd\u6e1b\u5c11\u3084\u5fc3\u8840\u7ba1\u7cfb\u3078\u306e\u5f71\u97ff\u304c\u5c11\u306a\u3044\u3001\u3088\u308a\u512a\u308c\u305f\u6cbb\u7642\u85ac\u3078\u306e\u30a2\u30af\u30bb\u30b9\u306f\u3001\u4fdd\u967a\u511f\u9084\u304c\u306a\u3044\u305f\u3081\u3001\u4e8c\u6b21\u6cbb\u7642\u306b\u9650\u3089\u308c\u3066\u3044\u307e\u3057\u305f\u3002\u305d\u306e\u7d50\u679c\u3001\u307b\u3068\u3093\u3069\u306e\u60a3\u8005\u3055\u3093\u306f\u3001NRDL (National Reimbursement Drug List) \u306e\u30ab\u30c6\u30b4\u30ea\u30fcA\u306b\u3088\u308b\u5b8c\u5168\u306a\u511f\u9084\u3092\u53d7\u3051\u306a\u304c\u3089\u3001\u5f93\u6765\u306e\u6cbb\u7642\u6cd5\u306e\u9078\u629e\u3092\u53d7\u3051\u7d9a\u3051\u305f\u305f\u3081\u3001\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u7387\u3084\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u306e\u4f4e\u3055\u306b\u60a9\u307e\u3055\u308c\u3066\u3044\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>\u306a\u305c\u3001T2D\u306f\u5f53\u5c40\u304c\u9032\u3081\u308b\u30a2\u30af\u30bb\u30b9\u3068\u511f\u9084\u306e\u6539\u9769\u306b\u304a\u3051\u308b\u7126\u70b9\u3068\u306a\u3063\u3066\u3044\u308b\u306e\u304b\uff1f<\/strong><\/h4>\n<p>\u4e2d\u56fd\u672c\u571f\u3067\u306f\u904e\u53bb10\u5e74\u9593\u306b\u7cd6\u5c3f\u75c5\u3068\u7cd6\u5c3f\u75c5\u5408\u4f75\u75c7\u306e\u6709\u75c5\u7387\u304c\u6025\u5897\u3057\u305f\u305f\u3081\u3001\u4e2d\u56fd\u5f53\u5c40\u306fT2D\u6cbb\u7642\u85ac\u3078\u306e\u60a3\u8005\u306e\u30a2\u30af\u30bb\u30b9\u3092\u3088\u308a\u81e8\u5e8a\u7684\u306b\u52b9\u679c\u7684\u306b\u6539\u5584\u3059\u308b\u3053\u3068\u3092\u6c42\u3081\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u4e2d\u56fd\u5f53\u5c40\u306eT2D\u306b\u5bfe\u3059\u308b\u95a2\u5fc3\u3092\u9ad8\u3081\u3066\u3044\u308b\u4e3b\u306a\u8981\u56e0\u306f\u4ee5\u4e0b\u306e\u901a\u308a\u3067\u3059\u3002<\/p>\n<ul>\n<li>\u4eca\u5f8c20\u5e74\u9593\u3067\u7cd6\u5c3f\u75c5\u4eba\u53e3\u304c\u5927\u5e45\u306b\u5897\u52a0\u3059\u308b\u3068\u4e88\u6e2c\u3055\u308c\u3066\u3044\u308b\u3053\u3068<sup>4<\/sup>\u3002\u3053\u308c\u306f\u3001\u6b27\u7c73\u306e\u98df\u751f\u6d3b\u30d1\u30bf\u30fc\u30f3\u3078\u306e\u9069\u5fdc\u304c\u9032\u307f\u3001\u5ea7\u308a\u304c\u3061\u306a\u30e9\u30a4\u30d5\u30b9\u30bf\u30a4\u30eb\u3084\u904b\u52d5\u4e0d\u8db3\u306e\u50be\u5411\u304c\u3042\u308b\u305f\u3081\u3067\u3059<\/li>\n<li>\u5927\u898f\u6a21\u306a\u7cd6\u5c3f\u75c5\u4eba\u53e3\u3092\u62b1\u3048\u308b\u4ed6\u56fd\u3068\u6bd4\u8f03\u3057\u3066\u3001\u8a3a\u65ad\u7387\u3068\u51e6\u65b9\u6cbb\u7642\u306e\u666e\u53ca\u7387\u304c\u6bd4\u8f03\u7684\u4f4e\u3044\u3053\u3068<sup>3<\/sup><\/li>\n<li>\u52b9\u679c\u7684\u306aT2D\u6cbb\u7642\u6cd5\u3078\u306e\u30a2\u30af\u30bb\u30b9\u304c\u4e0d\u5341\u5206\u306a\u305f\u3081\u3001\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u7387\u304c\u4f4e\u3044 (49%\u672a\u6e80)<sup>4<\/sup><\/li>\n<li>T2D\u306b\u95a2\u9023\u3059\u308b\u76f4\u63a5\u7684\u304a\u3088\u3073\u9593\u63a5\u7684\u306a\u533b\u7642\u8cbb\u304c\u5897\u5927\u3059\u308b\u305f\u3081\u3001\u533b\u7642\u5236\u5ea6\u306b\u5bfe\u3059\u308b\u6301\u7d9a\u7684\u306a\u8ca1\u653f\u8ca0\u62c5<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>2018\u5e74\u3001\u4e2d\u56fd\u672c\u571f\u3067\u306f\u3001\u4e3b\u8981\u306a\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u533b\u85ac\u54c1\u3092\u5bfe\u8c61\u3068\u3057\u305f\u6570\u91cf\u30d9\u30fc\u30b9\u306e\u8abf\u9054 (VBP) \u30d7\u30ed\u30b0\u30e9\u30e0\u3092\u5c0e\u5165\u3057\u307e\u3057\u305f\u3002\u3053\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u3067\u306f\u3001\u56fd\u5bb6\u533b\u7642\u4fdd\u969c\u5c40 (NHSA) \u304c\u3001GQCE (Generic Quality and Consistency Evaluation) \u57fa\u6e96\u3092\u9075\u5b88\u3057\u306a\u304c\u3089\u3001\u4e2d\u56fd\u672c\u571f\u306e\u60a3\u8005\u306b\u4f4e\u4fa1\u683c\u306e\u6cbb\u7642\u6cd5\u3092\u63d0\u4f9b\u3057\u3066\u3044\u308b\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u30e1\u30fc\u30ab\u30fc\u306b\u5bfe\u3057\u3066\u3001\u6570\u91cf\u8ca9\u58f2\u3092\u8a8d\u3081\u307e\u3057\u305f\u3002\u305d\u308c\u4ee5\u6765\u30015\u56de\u306b\u308f\u305f\u308bVBP\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u6210\u529f\u306b\u3088\u308a\u3001\u3044\u304f\u3064\u304b\u306eT2D\u6cbb\u7642\u85ac\u306e\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u533b\u85ac\u54c1\u306e\u4fa1\u683c\u304c\u5408\u7406\u5316\u3055\u308c\u307e\u3057\u305f (\u88681)\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u88681: \u4e2d\u56fd\u672c\u571f\u306b\u304a\u3051\u308bVBP\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u5bfe\u8c61\u3068\u306a\u308bT2D\u6cbb\u7642\u85ac\u306e\u30ea\u30b9\u30c8<\/strong><\/p>\n<table class=\"table\" style=\"font-size: 15px\" width=\"100%\">\n<tbody>\n<tr>\n<td width=\"12%\"><strong>VBP\u30e9\u30a6\u30f3\u30c9<\/strong><\/td>\n<td width=\"12%\"><strong>\u5e74\u6708<\/strong><\/td>\n<td width=\"12%\"><strong>\u6cbb\u7642\u85ac<\/strong><\/td>\n<td width=\"16%\"><strong>\u4f5c\u7528\u6a5f\u5e8f (MOA)<\/strong><\/td>\n<td width=\"12%\"><b>\u958b\u767a\u5143<\/b><\/td>\n<td width=\"12%\"><strong>\u5165\u672d\u4ef6\u6570<\/strong><\/td>\n<td width=\"12%\"><strong>\u958b\u767a\u5143\u306e\u843d\u672d\u6709\u7121<\/strong><\/td>\n<td width=\"12%\"><strong>\u5024\u4e0b\u3052\u7387<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>Round 2<\/strong><\/td>\n<td>2020\u5e741\u6708<\/td>\n<td>Acarbose<\/td>\n<td>Alpha-glucosidase inhibitors<\/td>\n<td>Bayer<\/td>\n<td>2<\/td>\n<td>\u6709<\/td>\n<td>92.1%<sup>5<\/sup> (brand)77.19<sup>8<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Glimepiride<\/td>\n<td>Sulfonylureas<\/td>\n<td>Sanofi<\/td>\n<td>5<\/td>\n<td>\u7121<\/td>\n<td>~53%<sup>9 <\/sup>(generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>Round 3<\/strong><\/td>\n<td>2020\u5e748\u6708<\/td>\n<td>Metformin<\/td>\n<td>Biguanides<\/td>\n<td>Bristol Myers Squibb<\/td>\n<td>8<\/td>\n<td>\u7121<\/td>\n<td>84.11%<sup>6<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Metformin sustained release<\/td>\n<td>Biguanides<\/td>\n<td>Merck<\/td>\n<td>8<\/td>\n<td>\u7121<\/td>\n<td>71.06%<sup>6<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Vildagliptin<\/td>\n<td>DPP-IV inhibitors<\/td>\n<td>Novartis<\/td>\n<td>6<\/td>\n<td>\u7121<\/td>\n<td>78.86%<sup>6<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>Round 4<\/strong><\/td>\n<td>2021\u5e742\u6708<\/td>\n<td>Empagliflozin<\/td>\n<td>SGLT-2 inhibitors<\/td>\n<td>Boehringer Ingelheim<\/td>\n<td>4<\/td>\n<td>\u7121<\/td>\n<td>55.93%<sup>7<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td width=\"72\"><strong>\u00a0<\/strong><\/td>\n<td width=\"84\"><\/td>\n<td width=\"82\">Canagliflozin<\/td>\n<td width=\"80\">SGLT-2 inhibitors<\/td>\n<td width=\"74\">J&amp;J<\/td>\n<td width=\"74\">2<\/td>\n<td width=\"78\">\u7121<\/td>\n<td width=\"80\">56.14%<sup>7<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Gliclazide<\/td>\n<td>Sulfonylureas<\/td>\n<td>Servier<\/td>\n<td>3<\/td>\n<td>\u7121<\/td>\n<td>53.46%<sup>7<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Nateglinide<\/td>\n<td>Meglitinides<\/td>\n<td>Novartis<\/td>\n<td>2<\/td>\n<td>\u7121<\/td>\n<td>14.56%<sup>7<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Repaglinide<\/td>\n<td>Meglitinides<\/td>\n<td>Novo Nordisk<\/td>\n<td>2<\/td>\n<td>\u7121<\/td>\n<td>65.55%<sup>7<\/sup> (generic)<\/td>\n<\/tr>\n<tr>\n<td><strong>Round 5<\/strong><sup>4<\/sup><\/td>\n<td>2021\u5e746\u6708<\/td>\n<td>Saxagliptin<\/td>\n<td>DPP-IV inhibitors<\/td>\n<td>AstraZeneca<\/td>\n<td>TBC<\/td>\n<td>TBC<\/td>\n<td>TBC<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Glipizide<\/td>\n<td>Sulfonylureas<\/td>\n<td>Pfizer<\/td>\n<td>TBC<\/td>\n<td>TBC<\/td>\n<td>TBC<\/td>\n<\/tr>\n<tr>\n<td><strong>\u00a0<\/strong><\/td>\n<td><\/td>\n<td>Miglitol<\/td>\n<td>Alpha-glucosidase inhibitors<\/td>\n<td>Sanofi<\/td>\n<td>TBC<\/td>\n<td>TBC<\/td>\n<td>TBC<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-size: small\">\u51fa\u5178: GBI analysis, Clarivate<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>\u533b\u5e2b\u3068\u60a3\u8005\u306f\u3001\u3053\u308c\u307e\u3067\u306b\u5b9f\u65bd\u3055\u308c\u305fVBP\u30e9\u30a6\u30f3\u30c9\u306e\u52b9\u679c\u3092\u5b9f\u611f\u3057\u59cb\u3081\u3066\u3044\u307e\u3059\u3002T2D\u6cbb\u7642\u306b\u95a2\u9023\u3059\u308b\u533b\u7642\u8cbb\u306f\u5927\u5e45\u306b\u524a\u6e1b\u3055\u308c\u3001\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u306eSGLT-2\u963b\u5bb3\u5264\u3084DPP-IV\u963b\u5bb3\u5264\u3078\u306e\u60a3\u8005\u306e\u30a2\u30af\u30bb\u30b9\u306f\u6539\u5584\u3055\u308c\u3001\u533b\u7642\u4fdd\u967a\u57fa\u91d1\u306f\u6301\u7d9a\u53ef\u80fd\u306a\u72b6\u614b\u3092\u7dad\u6301\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>\u8fd1\u5e74\u306e\u30a2\u30af\u30bb\u30b9\u304a\u3088\u3073\u511f\u9084\u5236\u5ea6\u306e\u6539\u9769\u306f\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u4fc3\u9032\u3057\u3001T2D\u5e02\u5834\u306e\u58f2\u4e0a\u3092\u5897\u5927\u3055\u305b\u7d9a\u3051\u3066\u3044\u308b<\/strong><\/h4>\n<p>SGLT-2\u963b\u5bb3\u5264\u3068GLP-1\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u306f\u3001\u5f93\u6765\u306eT2D\u6cbb\u7642\u85ac\u3068\u6bd4\u8f03\u3057\u3066\u6bd4\u8f03\u7684\u9ad8\u4fa1\u3067\u306f\u3042\u308b\u3082\u306e\u306e\u3001\u8840\u7cd6\u5024\u306e\u4f4e\u4e0b\u3001\u5fc3\u8840\u7ba1\u75be\u60a3\u3084\u4f53\u91cd\u6e1b\u5c11\u306a\u3069\u306e\u70b9\u3067\u3001\u60a3\u8005\u3055\u3093\u306b\u3068\u3063\u3066\u826f\u597d\u306a\u81e8\u5e8a\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb\u3092\u6709\u3057\u3066\u3044\u307e\u3059\u3002\u6700\u8fd1\u3001GLP-1\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u304c\u3059\u3079\u3066NRDL\u306b\u7d44\u307f\u5165\u308c\u3089\u308c\u305f\u3053\u3068\u3084\u3001VBP\u30d7\u30ed\u30b0\u30e9\u30e0\u306e\u7b2c4\u30e9\u30a6\u30f3\u30c9\u306b\u30a8\u30f3\u30d1\u30b0\u30ea\u30d5\u30ed\u30b8\u30f3\u304a\u3088\u3073\u30ab\u30ca\u30b0\u30ea\u30d5\u30ed\u30b8\u30f3\u306e\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u533b\u85ac\u54c1\u304c\u7d44\u307f\u5165\u308c\u3089\u308c\u305f\u3053\u3068\u3067\u3001T2D\u6cbb\u7642\u85ac\u5e02\u5834\u306b\u30dd\u30b8\u30c6\u30a3\u30d6\u306a\u52e2\u3044\u304c\u751f\u307e\u308c\u3066\u3044\u307e\u3059\u3002\u60a3\u8005\u3055\u3093\u306f\u3001\u8840\u7cd6\u5024\u3084\u6cbb\u7642\u6b74\u306b\u5fdc\u3058\u3066\u3001\u9ad8\u984d\u306a\u81ea\u5df1\u8ca0\u62c5\u3092\u3059\u308b\u3053\u3068\u306a\u304f\u3001\u5f8c\u7d9a\u306e\u6cbb\u7642\u30e9\u30a4\u30f3\u3067\u3088\u308a\u6027\u80fd\u306e\u9ad8\u3044\u85ac\u5264\u7fa4\u306b\u5207\u308a\u66ff\u3048\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3057\u305f\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u88682: \u4e2d\u56fd\u672c\u571f\u306b\u304a\u3051\u308b2019\u5e74\u304a\u3088\u30732020\u5e74\u306eNRDL\u30a2\u30c3\u30d7\u30c7\u30fc\u30c8\u306b\u542b\u307e\u308c\u308bT2D\u6cbb\u7642\u85ac\u306e\u30ea\u30b9\u30c8<\/strong><\/p>\n<table class=\"table\" style=\"font-size: 15px\" width=\"100%\">\n<thead class=\"thead-light\">\n<tr>\n<td width=\"20%\"><strong>\u6cbb\u7642\u85ac<\/strong><\/td>\n<td width=\"16%\"><strong>\u958b\u767a\u5143<\/strong><\/td>\n<td width=\"16%\"><strong>NRDL\u53ce\u8f09\u5e74<\/strong><\/td>\n<td width=\"16%\"><strong>\u5024\u4e0b\u3052\u7387<\/strong><\/td>\n<td width=\"16%\"><strong>NRDL\u53ce\u8f09\u524d\u306e\u58f2\u4e0a\u4e0a\u6607\u7387 (YoY)<\/strong><\/td>\n<td width=\"16%\"><strong>NRDL\u53ce\u8f09\u5f8c\u306e\u58f2\u4e0a\u4e0a\u6607\u7387 (YoY)<\/strong><\/td>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Dapagliflozin (Forxiga)<\/strong><\/td>\n<td style=\"text-align: center\">AstraZeneca<\/td>\n<td style=\"text-align: center\">2019<\/td>\n<td style=\"text-align: center\">72.68%<sup>10<\/sup><\/td>\n<td style=\"text-align: center\">95.9%<sup>4<\/sup><\/td>\n<td style=\"text-align: center\">206.7%<sup>4<\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>Insulin degludec (Tresiba)<\/strong><\/td>\n<td style=\"text-align: center\">Novo Nordisk<\/td>\n<td style=\"text-align: center\">2019<\/td>\n<td style=\"text-align: center\">8.48%<sup>10<\/sup><\/td>\n<td style=\"text-align: center\">443.75%<sup>4<\/sup><\/td>\n<td style=\"text-align: center\">380.45%<sup>4<\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>Empagliflozin (Jardiance)<\/strong><\/td>\n<td style=\"text-align: center\">Boehringer Ingelheim<\/td>\n<td style=\"text-align: center\">2019<\/td>\n<td style=\"text-align: center\">57%<sup>10<\/sup><\/td>\n<td style=\"text-align: center\">94.63%<sup>4<\/sup><\/td>\n<td style=\"text-align: center\">341.92%<sup>4<\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>Canagliflozin (Invokana)<\/strong><\/td>\n<td style=\"text-align: center\">J&amp;J<\/td>\n<td style=\"text-align: center\">2019<\/td>\n<td style=\"text-align: center\">58%<sup>10<\/sup><\/td>\n<td style=\"text-align: center\">556.52%<sup>4<\/sup><\/td>\n<td style=\"text-align: center\">34.73%<sup>4<\/sup> (generic entry)<\/td>\n<\/tr>\n<tr>\n<td><strong>Lixisenatide (Lyxumia)<\/strong><\/td>\n<td style=\"text-align: center\">Sanofi<\/td>\n<td style=\"text-align: center\">2019<\/td>\n<td style=\"text-align: center\">29%<sup>10<\/sup><\/td>\n<td style=\"text-align: center\">&#8211;<\/td>\n<td style=\"text-align: center\">1079.63%<sup>4<\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>Insulin degludec \/ insulin aspart (Ryzodeg)<\/strong><\/td>\n<td style=\"text-align: center\">Novo Nordisk<\/td>\n<td style=\"text-align: center\">2020<\/td>\n<td style=\"text-align: center\">47.4%<sup>11<\/sup><\/td>\n<td style=\"text-align: center\">875%<sup>4<\/sup><\/td>\n<td style=\"text-align: center\">76.28%<sup>4<\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>Dulaglutide (Trulicity)<\/strong><\/td>\n<td style=\"text-align: center\">Eli Lilly<\/td>\n<td style=\"text-align: center\">2020<\/td>\n<td style=\"text-align: center\">64.52%<sup>11<\/sup><\/td>\n<td style=\"text-align: center\">140.82%<sup>4<\/sup><\/td>\n<td style=\"text-align: center\">370.9%<sup>4<\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>Benaglutide (Yishengtai)<\/strong><\/td>\n<td style=\"text-align: center\">Shanghai Benemae Pharma<\/td>\n<td style=\"text-align: center\">2020<\/td>\n<td style=\"text-align: center\">54.52%<sup>11<\/sup><\/td>\n<td style=\"text-align: center\">68.53%<sup>4<\/sup><\/td>\n<td style=\"text-align: center\">122.2%<sup>4<\/sup><\/td>\n<\/tr>\n<tr>\n<td><strong>PEG loxenatide <\/strong><strong>(Fu Lai Mei)<\/strong><\/td>\n<td style=\"text-align: center\">Jiangsu Hansoh Pharmaceuticals<\/td>\n<td style=\"text-align: center\">2020<\/td>\n<td style=\"text-align: center\">58.68%<sup>11<\/sup><\/td>\n<td style=\"text-align: center\">&#8211;<\/td>\n<td style=\"text-align: center\">66.59%<sup>4<\/sup><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span style=\"font-size: small\">\u51fa\u5178: GBI analysis, Clarivate<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>\u30af\u30e9\u30ea\u30d9\u30a4\u30c8 China In-depth\u306e\u8a73\u7d30\u306a\u5206\u6790\u306b\u3088\u308b\u3068\u3001\u6bce\u5e74\u884c\u308f\u308c\u308bNRDL\u306e\u66f4\u65b0\u306f\u3001\u4e2d\u56fd\u672c\u571f\u3067\u9032\u5316\u3059\u308b\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u30fb\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u306e\u89e6\u5a92\u3068\u3057\u3066\u6a5f\u80fd\u3057\u3066\u3044\u307e\u3059\u3002\u3053\u308c\u307e\u3067VBP\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u53c2\u52a0\u3057\u3066\u3044\u306a\u304b\u3063\u305f\u591a\u56fd\u7c4d\u4f01\u696d (MNC) \u306f\u3001\u30b9\u30da\u30b7\u30e3\u30ea\u30c6\u30a3\u30c9\u30e9\u30c3\u30b0\u306e\u30dd\u30fc\u30c8\u30d5\u30a9\u30ea\u30aa\u306b\u7126\u70b9\u3092\u5f53\u3066\u3001NRDL\u3078\u306e\u767b\u9332\u3092\u78ba\u4fdd\u3059\u308b\u305f\u3081\u306b\u3001\u81e8\u5e8a\u7684\u6709\u7528\u6027\u3092\u5b9f\u8a3c\u3067\u304d\u308b\u9769\u65b0\u7684\u306a\u88fd\u54c1\u3092\u958b\u767a\u3059\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3057\u305f\u3002<\/p>\n<p>2019\u5e74\u304a\u3088\u30732020\u5e74\u306eNRDL\u66f4\u65b0 (\u30ab\u30c6\u30b4\u30ea\u30fcB) \u3078\u306e\u53c2\u5165\u4ea4\u6e09\u306b\u6210\u529f\u3057\u305f\u3044\u304f\u3064\u304b\u306eT2D\u6cbb\u7642\u85ac\u306f\u3001\u524d\u5e74\u6bd4\u3067\u597d\u8abf\u306a\u58f2\u4e0a\u3092\u8a18\u9332\u3057\u3066\u304a\u308a (\u88682)\u3001\u4f4e\u4fa1\u683c\u3068\u90e8\u5206\u7684\u306a\u511f\u9084\u306b\u3088\u308b\u826f\u597d\u306a\u60a3\u8005\u306e\u53d6\u308a\u8fbc\u307f\u3092\u793a\u5506\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>\u4e2d\u56fd\u672c\u571f\u306e\u8fb2\u6751\u90e8\u306f\u3001\u533b\u85ac\u54c1\u958b\u767a\u8005\u306b\u3068\u3063\u3066\u30a2\u30af\u30bb\u30b9\u62e1\u5927\u306e\u5927\u304d\u306a\u6a5f\u4f1a\u3068\u306a\u308b<\/strong><\/h4>\n<p>\u8fb2\u6751\u90e8\u3067\u306f\u3001\u90fd\u5e02\u90e8\u306b\u6bd4\u3079\u3066\u7cd6\u5c3f\u75c5\u306b\u3088\u308b\u6b7b\u4ea1\u7387\u304c\u9ad8\u304f\u3001\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u7387\u3092\u5411\u4e0a\u3055\u305b\u308b\u305f\u3081\u306b\u3001\u3088\u308a\u52b9\u679c\u7684\u3067\u5fcd\u5bb9\u6027\u304c\u9ad8\u304f\u3001\u8cbb\u7528\u5bfe\u52b9\u679c\u306e\u9ad8\u3044\u6cbb\u7642\u6cd5\u306b\u5bfe\u3059\u308b\u30a2\u30f3\u30e1\u30c3\u30c8\u30cb\u30fc\u30ba\u304c\u9ad8\u3044\u3053\u3068\u304c\u793a\u5506\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u56fd\u5bb6\u533b\u7642\u4fdd\u969c\u5c40\u306f\u3001T2D\u306b\u51e6\u65b9\u3055\u308c\u308b\u30a4\u30f3\u30b9\u30ea\u30f3\u3092\u542b\u3080\u4e2d\u56fd\u672c\u571f\u306e\u65e2\u5b58\u304a\u3088\u3073\u65b0\u898f\u306e\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u533b\u85ac\u54c1\/\u30d0\u30a4\u30aa\u30b7\u30df\u30e9\u30fc\u533b\u85ac\u54c1\u306e\u307b\u3068\u3093\u3069\u3092VBP\u306e\u5bfe\u8c61\u3068\u3059\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u304a\u308a\u3001\u8fb2\u6751\u90e8\u306e\u60a3\u8005\u306f\u4eca\u5f8c10\u5e74\u9593\u3067\u3088\u308a\u52b9\u679c\u7684\u306aT2D\u6cbb\u7642\u6cd5\u3078\u306e\u30a2\u30af\u30bb\u30b9\u304c\u6539\u5584\u3055\u308c\u308b\u3053\u3068\u304c\u671f\u5f85\u3067\u304d\u307e\u3059\u3002<\/p>\n<p>\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u4e88\u6e2c\u3067\u306f\u3001\u4e2d\u56fd\u672c\u571f\u3067\u306e\u767a\u58f2\u304c\u4e88\u5b9a\u3055\u308c\u3066\u3044\u308b\u4ed6\u306e\u3044\u304f\u3064\u304b\u306e\u6cbb\u7642\u85ac (\u30bb\u30de\u30b0\u30eb\u30c1\u30c9\u3084\u30c9\u30eb\u30b6\u30b0\u30ea\u30a2\u30c1\u30f3\u306a\u3069) \u304c\u826f\u597d\u306a\u81e8\u5e8a\u30c7\u30fc\u30bf\u3092\u793a\u3057\u3066\u3044\u308b\u3053\u3068\u304b\u3089\u3001\u4eca\u5f8c10\u5e74\u9593\u3067T2D\u6cbb\u7642\u306e\u30d1\u30e9\u30c0\u30a4\u30e0\u304c\u5927\u304d\u304f\u5909\u5316\u3059\u308b\u53ef\u80fd\u6027\u304c\u9ad8\u3044\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>\u3053\u306e\u8a18\u4e8b\u306f\u3001\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30a2\u30ca\u30ea\u30b9\u30c8\u304cChina In-Depth\u306e\u30c7\u30fc\u30bf\u3068\u5206\u6790\u3092\u3082\u3068\u306b\u4f5c\u6210\u3057\u305f\u3082\u306e\u3067\u3059\u3002China In-Depth\u306b\u306f\u3001\u60a3\u8005\u6570\u3001\u30a2\u30af\u30bb\u30b9\u3068\u511f\u9084\u306e\u74b0\u5883\u3001\u6cbb\u7642\u30d1\u30e9\u30c0\u30a4\u30e0\u3001\u30d1\u30a4\u30d7\u30e9\u30a4\u30f3\u3001\u85ac\u5264\u30ec\u30d9\u30eb\u306e\u4e88\u6e2c\u306a\u3069\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p>\u4e2d\u56fd\u672c\u571f\u306e\u30d8\u30eb\u30b9\u30b1\u30a2\u5e02\u5834\u3068\u75be\u60a3\u5225\u30c8\u30ec\u30f3\u30c9\u306b\u95a2\u3059\u308b\u60c5\u5831\u306b<a href=\"https:\/\/decisionresourcesgroup.com\/solutions\/market-assessment-suite\/introducing-china-in-depth\/\" target=\"_blank\" rel=\"noopener\">\u30a2\u30af\u30bb\u30b9\u3067\u304d\u307e\u3059<\/a>\u3002<\/p>\n<p>China In-Depth\u306e\u304a\u5ba2\u69d8\u306f\u3001\u4e2d\u56fd\u672c\u571f\u306eT2D\u6cbb\u7642\u5e02\u5834\u306b\u95a2\u3059\u308b\u8457\u8005\u306e\u5168\u30ec\u30dd\u30fc\u30c8\u306b<a href=\"https:\/\/insights.decisionresourcesgroup.com\/disease\/type-2-diabetes\/geographic-focus-china\/type-2-diabetes-china-in-depth-china-2021\/section\/china-in-depth-type-2-diabetes\" target=\"_blank\" rel=\"noopener\">\u3053\u3061\u3089<\/a>\u304b\u3089\u30a2\u30af\u30bb\u30b9\u3067\u304d\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<div style=\"font-size: 14px\">\n<p><strong>References:<\/strong><\/p>\n<p><sup>1<\/sup> Diabetes in China (2019). Diabetes.co.uk, [online]. Available at: https:\/\/www.diabetes.co.uk\/global-diabetes\/diabetes-in-china.html (Accessed 20 June 2021)<\/p>\n<p><sup>2<\/sup> China (2020). International Diabetes Federation, [online]. Available at: <a href=\"https:\/\/idf.org\/our-network\/regions-members\/western-pacific\/members\/101-china.html\" target=\"_blank\" rel=\"noopener\">https:\/\/idf.org\/our-network\/regions-members\/western-pacific\/members\/101-china.html<\/a> (Accessed 22 June 2021)<\/p>\n<p><sup>3<\/sup> Deepening Health Reform in China (2016). Healthy China, [online]. Available at: <a href=\"http:\/\/www.indiaenvironmentportal.org.in\/files\/file\/HealthReformInChina.pdf\" target=\"_blank\" rel=\"noopener\">http:\/\/www.indiaenvironmentportal.org.in\/files\/file\/HealthReformInChina.pdf<\/a> (Accessed 23 June 2021)<\/p>\n<p><sup>4<\/sup>Clarivate China In-Depth analysis<\/p>\n<p><sup>5 <\/sup>China launches price war to reshuffle pharma industry (2020). BioWorld, [online]. Available at: https:\/\/www.bioworld.com\/articles\/432505-china-launches-price-war-to-reshuffle-pharma-industry-bayer-cuts-prices-by-90-to-secure-market?v=preview (Accessed 23 June 2021)<\/p>\n<p><sup>6<\/sup> China\u2019s Third VBP Round (2020). China Pharmaceutical &amp; Biotechnology review, [online]<\/p>\n<p><sup>7<\/sup> China\u2019s 4<sup>th<\/sup> VBP Round (2021). China Pharmaceutical &amp; Biotechnology review, [online]<\/p>\n<p><sup>8 <\/sup>Second round VBP tender completed amid contention (2020). GBI Source, [online]<\/p>\n<p><sup>9 <\/sup>Sanofi: Global grows 2.8% in 2019, China nosedives 21% in Q4 (2020). GBI Source, [online]<\/p>\n<p><sup>10<\/sup> Innovation Momentum (2019). China Pharmaceutical &amp; Biotechnology review, [online]<\/p>\n<p><sup>11<\/sup> GBI analysis<\/p>\n<\/div>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u82f1\u8a9e\u539f\u6587\u30b5\u30a4\u30c8 \u672c\u8a18\u4e8b\u306f\u82f1\u6587\u30d6\u30ed\u30b0\u3092\u65e5\u672c\u8a9e\u306b\u7ffb\u8a33\u518d\u7de8\u96c6\uff08\u4e00\u90e8\u8ffd\u8a18\u3092\u542b\u3080\uff09\u3057\u305f\u3082\u306e\u3067\u3059\u3002\u672c\u8a18\u4e8b\u306e\u6b63\u5f0f\u8a00\u8a9e\u306f\u82f1\u8a9e\u3067\u3042\u308a\u3001\u305d\u306e\u5185\u5bb9\u30fb\u89e3\u91c8\u306b\u3064\u3044\u3066\u306f\u82f1\u8a9e\u304c\u512a\u5148\u3057\u307e\u3059\u3002 &nbsp; KARAN VERMA Principal Analyst, Clarivate &nbsp; \u4e2d\u56fd\u672c\u571f\u3067\u306f\u8fd1\u5e74\u3001\u30c0\u30a4\u30ca\u30df\u30c3\u30af\u306a\u7d4c\u6e08\u72b6\u6cc1\u3084\u4eba\u53e3\u52d5\u614b\u306b\u5bfe\u5fdc\u3059\u308b\u305f\u3081\u306b\u3001\u898f\u5236\u3084\u511f\u9084\u306b\u95a2\u3059\u308b\u4e00\u9023\u306e\u6539\u9769\u304c\u884c\u308f\u308c\u3066\u304d\u307e\u3057\u305f\u3002\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u5e02\u5834\u8a55\u4fa1\u30a8\u30ad\u30b9\u30d1\u30fc\u30c8\u3067\u3042\u308bKaran Verma\u304c\u3001\u4e2d\u56fd\u672c\u571f\u306e2\u578b\u7cd6\u5c3f\u75c5\u5e02\u5834\u306b\u304a\u3051\u308b\u3053\u308c\u3089\u306e\u6539\u9769\u306e\u5f79\u5272\u3068\u3001\u9769\u65b0\u7684\u306a\u533b\u85ac\u54c1\u3078\u306e\u30a2\u30af\u30bb\u30b9\u3092\u3069\u306e\u3088\u3046\u306b\u5e83\u3052\u3089\u308c\u308b\u304b\u306b\u3064\u3044\u3066\u89e3\u8aac\u3057\u307e\u3059\u3002 &nbsp; \u4e2d\u56fd\u672c\u571f\u306e2\u578b\u7cd6\u5c3f\u75c5\u306f\u9ad8\u3044\u6210\u9577\u7387\u3092\u7dad\u6301\u3057\u3066\u3044\u308b \u4e2d\u56fd\u672c\u571f\u3067\u306f\u300110\u4eba\u306b1\u4eba\u3001\u7d041\u51044,000\u4e07\u4eba\u304c2\u578b\u7cd6\u5c3f\u75c5\u3092\u60a3\u3063\u3066\u3044\u308b\u3068\u63a8\u5b9a\u3055\u308c\u3066\u3044\u307e\u30591,4\u3002\u3053\u308c\u306f\u3001\u904e\u53bb\u6570\u5341\u5e74\u306b\u308f\u305f\u308b\u4e2d\u56fd\u306e\u6025\u901f\u306a\u90fd\u5e02\u5316\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002\u4e2d\u56fd\u3067\u306f\u3001\u30d6\u30c9\u30a6\u7cd6\u306e\u8178\u7ba1\u5438\u53ce\u3092\u4f4e\u4e0b\u3055\u305b\u3001\u30a4\u30f3\u30b9\u30ea\u30f3\u611f\u53d7\u6027\u3092\u9ad8\u3081\u308b\u3053\u3068\u3067\u8840\u7cd6\u5024\u3092\u9069\u5207\u306b\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u3059\u308b\u3001\u3044\u304f\u3064\u304b\u306e\u6297\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85ac\u304c\u8ca9\u58f2\u3055\u308c\u3066\u3044\u307e\u30594\u3002 &nbsp; \u52b9\u679c\u7684\u306aT2D\u6cbb\u7642\u85ac\u306e\u5c0e\u5165\u3092\u59a8\u3052\u3066\u3044\u308b\u65ad\u7247\u7684\u306a\u898f\u5236\u74b0\u5883 \u5f93\u6765\u3001\u4e2d\u56fd\u672c\u571f\u306eT2D\u60a3\u8005\u306e\u591a\u304f\u306f\u3001\u5165\u624b\u306e\u3057\u3084\u3059\u3055\u3001\u8cbb\u7528\u5bfe\u52b9\u679c\u306e\u9ad8\u3044\u30b8\u30a7\u30cd\u30ea\u30c3\u30af\u533b\u85ac\u54c1\u306e\u5165\u624b\u53ef\u80fd\u6027\u3001HbA1c\u5024\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u52b9\u679c\u306e\u8a8d\u8b58\u306a\u3069\u304b\u3089\u3001\u30d5\u30a1\u30fc\u30b9\u30c8\u30e9\u30a4\u30f3\u6cbb\u7642\u3067\u306f\u30e1\u30c8\u30db\u30eb\u30df\u30f3\u3001\u30bb\u30ab\u30f3\u30c9\u30e9\u30a4\u30f3\u6cbb\u7642\u3067\u306f\u30a2\u30ab\u30eb\u30dc\u30fc\u30b9\u3001\u30b9\u30eb\u30db\u30cb\u30eb\u5c3f\u7d20\u3001\u30c1\u30a2\u30be\u30ea\u30b8\u30f3\u7cfb\u85ac\u5264\u306a\u3069\u306e\u6a19\u6e96\u7684\u306a\u6297\u7cd6\u5c3f\u75c5\u6cbb\u7642\u3092\u53d7\u3051\u3066\u304d\u307e\u3057\u305f\u3002\u3053\u308c\u3089\u306e\u6cbb\u7642\u85ac\u306b\u306f\u3001\u4f53\u91cd\u5897\u52a0\u3001\u5fc3\u8840\u7ba1\u7cfb\u306e\u5b89\u5168\u6027\u306b\u95a2\u3059\u308b\u61f8\u5ff5\u3001\u4f4e\u8840\u7cd6\u306e\u767a\u751f\u7387\u306e\u9ad8\u3055\u306a\u3069\u306e\u526f\u4f5c\u7528\u304c\u3042\u308b\u3082\u306e\u306e\u3001\u8840\u7cd6\u5024\u3092\u4e0b\u3052\u308b\u52b9\u679c\u304c\u3042\u308b\u305f\u3081\u3001\u4f7f\u7528\u7387\u306f\u9ad8\u3044\u307e\u307e\u3067\u3057\u305f\u3002 \u3057\u304b\u3057\u3001SGLT-2\u963b\u5bb3\u5264\u3084GLP-1\u53d7\u5bb9\u4f53\u4f5c\u52d5\u85ac\u306a\u3069\u3001\u5f93\u6765\u306e\u6cbb\u7642\u85ac\u3088\u308a\u3082\u4f53\u91cd\u6e1b\u5c11\u3084\u5fc3\u8840\u7ba1\u7cfb\u3078\u306e\u5f71\u97ff\u304c\u5c11\u306a\u3044\u3001\u3088\u308a\u512a\u308c\u305f\u6cbb\u7642\u85ac\u3078\u306e\u30a2\u30af\u30bb\u30b9\u306f\u3001\u4fdd\u967a\u511f\u9084\u304c\u306a\u3044\u305f\u3081\u3001\u4e8c\u6b21\u6cbb\u7642\u306b\u9650\u3089\u308c\u3066\u3044\u307e\u3057\u305f\u3002\u305d\u306e\u7d50\u679c\u3001\u307b\u3068\u3093\u3069\u306e\u60a3\u8005\u3055\u3093\u306f\u3001NRDL (National Reimbursement Drug List) \u306e\u30ab\u30c6\u30b4\u30ea\u30fcA\u306b\u3088\u308b\u5b8c\u5168\u306a\u511f\u9084\u3092\u53d7\u3051\u306a\u304c\u3089\u3001\u5f93\u6765\u306e\u6cbb\u7642\u6cd5\u306e\u9078\u629e\u3092\u53d7\u3051\u7d9a\u3051\u305f\u305f\u3081\u3001\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u7387\u3084\u30b3\u30f3\u30d7\u30e9\u30a4\u30a2\u30f3\u30b9\u306e\u4f4e\u3055\u306b\u60a9\u307e\u3055\u308c\u3066\u3044\u307e\u3057\u305f\u3002 &nbsp; \u306a\u305c\u3001T2D\u306f\u5f53\u5c40\u304c\u9032\u3081\u308b\u30a2\u30af\u30bb\u30b9\u3068\u511f\u9084\u306e\u6539\u9769\u306b\u304a\u3051\u308b\u7126\u70b9\u3068\u306a\u3063\u3066\u3044\u308b\u306e\u304b\uff1f \u4e2d\u56fd\u672c\u571f\u3067\u306f\u904e\u53bb10\u5e74\u9593\u306b\u7cd6\u5c3f\u75c5\u3068\u7cd6\u5c3f\u75c5\u5408\u4f75\u75c7\u306e\u6709\u75c5\u7387\u304c\u6025\u5897\u3057\u305f\u305f\u3081\u3001\u4e2d\u56fd\u5f53\u5c40\u306fT2D\u6cbb\u7642\u85ac\u3078\u306e\u60a3\u8005\u306e\u30a2\u30af\u30bb\u30b9\u3092\u3088\u308a\u81e8\u5e8a\u7684\u306b\u52b9\u679c\u7684\u306b\u6539\u5584\u3059\u308b\u3053\u3068\u3092\u6c42\u3081\u3066\u3044\u307e\u3059\u3002 \u4e2d\u56fd\u5f53\u5c40\u306eT2D\u306b\u5bfe\u3059\u308b\u95a2\u5fc3\u3092\u9ad8\u3081\u3066\u3044\u308b\u4e3b\u306a\u8981\u56e0\u306f\u4ee5\u4e0b\u306e\u901a\u308a\u3067\u3059\u3002 \u4eca\u5f8c20\u5e74\u9593\u3067\u7cd6\u5c3f\u75c5\u4eba\u53e3\u304c\u5927\u5e45\u306b\u5897\u52a0\u3059\u308b\u3068\u4e88\u6e2c\u3055\u308c\u3066\u3044\u308b\u3053\u30684\u3002\u3053\u308c\u306f\u3001\u6b27\u7c73\u306e\u98df\u751f\u6d3b\u30d1\u30bf\u30fc\u30f3\u3078\u306e\u9069\u5fdc\u304c\u9032\u307f\u3001\u5ea7\u308a\u304c\u3061\u306a\u30e9\u30a4\u30d5\u30b9\u30bf\u30a4\u30eb\u3084\u904b\u52d5\u4e0d\u8db3\u306e\u50be\u5411\u304c\u3042\u308b\u305f\u3081\u3067\u3059 \u5927\u898f\u6a21\u306a\u7cd6\u5c3f\u75c5\u4eba\u53e3\u3092\u62b1\u3048\u308b\u4ed6\u56fd\u3068\u6bd4\u8f03\u3057\u3066\u3001\u8a3a\u65ad\u7387\u3068\u51e6\u65b9\u6cbb\u7642\u306e\u666e\u53ca\u7387\u304c\u6bd4\u8f03\u7684\u4f4e\u3044\u3053\u30683 \u52b9\u679c\u7684\u306aT2D\u6cbb\u7642\u6cd5\u3078\u306e\u30a2\u30af\u30bb\u30b9\u304c\u4e0d\u5341\u5206\u306a\u305f\u3081\u3001\u8840\u7cd6\u30b3\u30f3\u30c8\u30ed\u30fc\u30eb\u7387\u304c\u4f4e\u3044&#8230;<\/p>\n","protected":false},"author":161,"featured_media":3434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[1309,1297,1300,1228],"tags":[],"class_list":["post-3429","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","category-blog","category-cortellis","category-life-sciences-healthcare","clarivate-industry-life-sciences-and-healthcare","clarivate-product-biopharma","clarivate-product-hospital-healthcare-provider"],"acf":[],"lang":"ja","translations":{"ja":3429},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/3429","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/161"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=3429"}],"version-history":[{"count":0,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/3429\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/3434"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=3429"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=3429"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=3429"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}